NMT2 Biomarker Detection for Colorectal Cancer Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current colorectal cancer (CRC) screening methods, such as Fecal Occult Blood Testing, Sigmoidoscopy, and Colonoscopy, face low compliance due to invasiveness, high false positives, and limited sensitivity, necessitating a more effective screening approach.
Innovation Solution
Measuring N-myristoylatransferase 2 (NMT2) levels in patient samples using specific antibodies or nucleic acid sequences to identify candidates for further CRC screening, potentially through sigmoidoscopy or colonoscopy, as elevated NMT2 levels indicate a higher risk for CRC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Fecal Occult Blood Testing (FOBT) is used for CRC screening, then cost effectiveness is improved, but false positive rates increase and patient compliance decreases
Solution Approach 1:
The invention changes the measured parameter from general blood presence (FOBT) to specific NMT2 enzyme activity levels. By measuring NMT2 activity as a biomarker, the test maintains the simplicity and low cost of FOBT while improving reliability through a more specific cancer-related marker that reduces false positives caused by diet or medication.
2Measurement precision
If Sigmoidoscopy and Colonoscopy are used for CRC screening, then detection sensitivity is improved, but invasiveness increases and patient compliance decreases
Solution Approach 1:
The invention introduces NMT2 enzyme activity measurement as an intermediary biomarker test. This non-invasive blood test serves as a mediator between simple FOBT and invasive endoscopy, providing enhanced detection sensitivity through specific cancer marker measurement while avoiding the invasiveness and procedural risks of sigmoidoscopy and colonoscopy.
3Ease of operation
If Carcinoembryonic Antigen (CEA) is used as a biomarker, then blood test availability is improved, but sensitivity and specificity decrease
Solution Approach 1:
The invention changes the biomarker parameter from CEA (a general tumor marker with limited specificity) to NMT2 enzyme activity (a specific marker for colorectal cancer). This parameter change maintains the ease of blood test measurement while significantly improving both sensitivity and specificity for CRC detection, as NMT2 activity is specifically elevated in CRC patients.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively identifies CRC candidates by distinguishing NMT2 overexpression in T-cells, offering a non-invasive and sensitive approach to improve patient compliance and early detection of CRC.
Implementation Method 1
measuring N-myristoylatransferase 2 (NMT2) levels in a sample from a patient by using a measuring reagent which is specific to NMT2 compared to NMT1
Implementation Method 2
N-myristoylation is the covalent attachment of a 14-carbon saturated fatty acid chain to the N-terminal glycine residue of a protein that is catalyzed by the enzyme N-myristoylatransferase (NMT)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein is the Identification of the NMT isozyme overexpressed in PBMCs of colorectal cancer patients and the cell types overexpressing NMT2 in the PBMCs of CRC patients.